Pfizer has struck a collaboration with Innovent Biologics to discover and develop 12 early-stage antibodies and antibody-drug conjugates (ADCs) targeting multiple cancers. The deal could yield up to $10.5 billion for the Chinese biotech, marking one of the largest oncology partnerships of the year.
Under the agreement, the companies will focus on de novo antibodies and ADCs that have not yet entered clinical trials. The partnership combines Pfizer's global development and commercialization infrastructure with Innovent's discovery platform, though specific targets and mechanisms remain undisclosed.
No timelines for IND filings or clinical entry have been announced, reflecting the early-stage nature of the pipeline. The collaboration does not involve any currently marketed products or late-stage assets, meaning financial returns will take years to materialize.
For Innovent, the deal provides a significant financial cushion and validation of its research capabilities. Pfizer gains access to a broad set of novel cancer biologics without upfront acquisition costs, though the licensing fees and milestone payments structure was not detailed.
The oncology ADC space is increasingly crowded, with dozens of companies pursuing similar technologies. Innovent must demonstrate that its candidates can differentiate on efficacy or safety to justify the blockbuster backing from Pfizer.